{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}],"units":"Participants"}],"groups":[{"description":"Velcade 1.0 mg/m\\^2 Velcade 1.3 mg/m\\^2 D1,4, 8, 11 (x 6 cycles, then 1.0 mg/m\\^2 (for cycles 7-12) Thalidomide 100 mg D1-28 Dexamethasone 20 mg D1-4 and 8-11","id":"BG000","title":"Velcade, Thalidomide, and Dexamethasone"},{"description":"VMD:\n\nVelcade 1.3 mg/m\\^2 D1, 4, 7, 10 (x6 mo, then 1.0 mg/m\\^2) Melphalan 4 (6, 8, 10) mg/m\\^2 D1, 4, 7, 10 dose escalation Dexamethasone 20 mg 1-4 and 7-10","id":"BG001","title":"VMD With Melphalan Dose Escalation"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}